Seminars in Oncology
Volume 35, Issue 2 , Pages 183-191 , April 2008

Diagnosis and Management of Peritoneal Carcinomatosis Arising From Adenocarcinoma of the Colon and Rectum

  • Richard E. Royal
    • ,
  • James F. Pingpank Jr

      Affiliations

    • Corresponding Author InformationAddress correspondence to James F. Pingpank Jr, MD, Surgical Metabolism Section, Surgery Branch, NCI, NIH, CRC, Building 10, Room 4W-5932, 10 Center Dr, MSC-1201, Bethesda, MD 20892.

References 

  1. Henriksen JH, Winkler K. Peritoneum and ascites formation. In:  Bengmark S editors. The peritoneum and peritoneal access. London: Wright Publishers; 1989;p. 94
  2. Feldman GB, Knapp RC, Order SE, Hellman S. The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. Cancer Res. 1972;32:1663
  3. Garrison RN, Galloway RH, Heuser LS. Mechanisms of malignant ascites production. J Surg Res. 1987;42:126
  4. Flessner MF, Fenstermachner JD, Blasberg RG, Dedrick RL. Peritoneal absorption of macromolecules studied by quantitative autoradiography. Am J Physiol. 1985;248:H26
  5. Sugarbaker P. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. In:  Sugarbaker P editors. Peritoneal carcinomatosis: principles of management. Boston: Kluwer Academic; 1996;p. 79
  6. Hagiwara A, Rakanhashi T, Sawai K, et al. Milky spots at the implantation site for malignant cells in peritoneal dissemination in mice. Cancer Res. 1993;53:687
  7. Ronnet BM, Shmookler BM, Sugarbaker PH, Kurman RJ. Pseudomyxoma peritonei: new concepts in diagnosis, origin, nomeclature, and relationship to mucinous borderline (low malignant potential) tumors of the ovary. Anat Pathol. 1997;2:197
  8. Weiss L. Metastatic inefficiency: intravascular and intraperitoneal implantation of cancer cells. Cancer Treat Res. 1996;82:1
  9. Archer AG, Sugarbaker PH, Jelinek JS. Radiology of peritoneal carcinomatosis. Cancer Treat Res. 1996;82:263
  10. Low RN, Semelka RC, Worawattarakul S, Alzate GD, Sigeti JS. Extrahepatic abdominal imaging in patients with malignancy: comparison of MR imaging and helical CT, with subsequent surgical correlation. Radiology. 1999;21:625
  11. Balestreri L, Bison L, Sorio R, et al. Abdominal recurrence of ovarian cancer: value of abdominal MR in patients with positive CA125 and negative CT. Radiol Med. 2002;104:426
  12. Fong Y, Saldinger PF, Akhurst T, et al. Utility of 18F-FDG postiron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg. 1999;178:282
  13. Turlakow A, Yeung HW, Salmon AS, Macapinlac HA, Larson SM. Peritoneal carcinomatosis: role of 18F-FDG PET. J Nucl Med. 2003;44:1407
  14. Kanellos I, Demetriades H, Zintzaras E, et al. Incidence and porgnostic value of positive peritoneal cytology in colorectal cancer. Dis Colon Rectum. 2003;46:535
  15. Nakatsuka A, Yamaguchi K, Shimizu S, et al. Positive washing cytology in patients with pancreatic cancer indicates a contraindication of pancreatectomy. Int J Surg Invest. 1999;1:311
  16. Werth H. Klinische und anatomische untersuchungen zue lehre von deh bauchgeschwuelsten und der laparotomie. Arch Gynaekol. 1884;24:100
  17. Ronnet BM, Zahn CM, Kurman RJ, et al. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. Am J Surg Pathol. 1995;19:1390
  18. Ronnet BM, Yan H, Kurman RJ, Shmookler BM, Wu L, Sugarbaker PH. Patients with Pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer. 2001;92:85
  19. van Ruth S, Acherman YIZ, van de Vijvert MJ, Hart AAM, Verwaal VJ, Zoetmulder FAN. Pseudomyxoma peritonei: a review of 62 cases. Eur J Surg Oncol. 2003;29:682
  20. Gough DB, Donohue JH, Schutt AJ, Gonchoroff N, et al. Pseudomyxoma peritonei: long-term patient survival with an aggressive regional approach. Ann Surg. 1994;219:112
  21. Harshen R, Jyothirmayi R, Mithal N. Pseudomyxoma peritonei. Clin Oncol. 2003;15:73
  22. Green JB, Timmcke AE, Mitchell WT, Hicks TC, Gathright JB, Ray JE. Mucinous carcinoma—just another colon cancer?. Dis Colon Rectum. 1993;36:49
  23. Nitecki SS, Wolff BG, Schlinkert R, Sarr MG. The natural history of surgically treated primary adenocarcinoma of the appendix. Ann Surg. 1994;219:51
  24. Pingpank JF, Libutti SK, Bartlett DL, Kranda KC, et al. Aggressive surgical resection/debulking and continuous hyperthermic peritoneal perfusion (CHPP) with cisplatin (CDDP) for patients with peritoneal carcinomatosis from primary gastrointestinal adenocarcinoma. Proc Am Assoc Cancer Res. 2003;2:R4487
  25. Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg. 1995;221:124
  26. Elias D, Blot F, El Otmany A, Antoun S, Lasser P, et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer. 2001;92:71
  27. Roviello F, Marrelli D, de Manzoni G, Morgagni P, et al. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg. 2003;90:1113
  28. Culliford AT, Brooks AD, Sharma S, Saltz LB, et al. Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer. Ann Surg Oncol. 2001;8:787
  29. Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737
  30. Shen P, Hawksworth J, Lovato J, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol. 2004;11:178
  31. Glehen O, Cotte E, Schreiber V, Sayag-Beaujard AC, Vignal J, Gilly FN. Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br J Surg. 2004;91:747
  32. Lennon AM, Mulcahy HE, Hyland JMP, Lowry C, et al. Peritoneal involvement in stage II colon cancer. Am J Clin Pathol. 2003;119:108
  33. Leach SD, Rose JA, Lowy AM, Lee JE, et al. Significance of peritoneal cytology in patients with potentially resectable adenocarcinoma of the pancreatic head. Surgery. 1995;118:472
  34. Yu W, Whang I, Averbach A, Chang D, Sugarbaker PH. Morbidity and mortality of early postoperative intraperitoneal chemotherapy as adjuvant therapy for gastric cancer. Am Surg. 1998;64:1104
  35. Sautner T, Hofbauer F, Depisch D, Schiessel R, Jakesz R. Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol. 1994;12:970
  36. Ikeguchi M, Kondou A, Oka A, Tsujitani S, Maeta M, Kaibara N. Effects of continuous hyperthermic peritoneal perfusion on prognosis of gastric cancer with serosal invasion. Eur J Surg. 1995;161:581
  37. Portilla AG, Sugarbaker PH, Chang D. Second-look surgery after cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analysis of prognostic features. World J Surg. 1999;23:23
  38. Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol. 1999;72:278
  39. Alexander HR, Bartlett DL, Libutti SK. National Cancer Institute experience with regional therapy for unresectable primary and metastatic cancer of the liver or peritoneal cavity. In:  Markman M editors. Regional chemotherapy; clinical research and practice (current clinical oncology). Totowa, NJ: Humana Press; 2000;p. 127
  40. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29
  41. Los G, Mutsaers PH, van der Vijgh WJ, et al. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res. 1989;49:3380
  42. Sugarbaker PH, Gianola FJ, Speyer JC, et al. Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgery. 1985;98:414
  43. Alberts DS, Liu PY, Hannigan EV, O’Toole R, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950
  44. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34
  45. Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol. 1999;43:S15
  46. Benoit L, Duvillard C, Rat P, Chauffert B. The effect of intra-abdominal temperature on the tissue and tumor diffusion of intraperitoneal cisplatin in a model of peritoneal carcinomatosis in rats. Chirurgie. 1999;124:375
  47. Menon C, Kutney SN, Lehr SC, Hendren SK, et al. Vascularity and uptake of photosensitizer in small human tumor nodules: implications for intraperitoneal photodynamic therapy. Clin Cancer Res. 2001;7:3904
  48. Lechanteur C, Pricen F, Lo Bue S, et al. HSV-1 thymidine kinase gene therapy for peritoneal carcinomatosis. Adv Exp Med Biol. 1998;341:119
  49. Fujiyama J, Nakase Y, Osaki K, et al. Cisplatin incorporated microspheres: development and fundamental studies for its clinical application. J Control Release. 2003;89:397
  50. Milenic DE, Garmestani K, Brady ED, et al. Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother Radiopharm. 2005;20:557
  51. Blair SL, Chu DZJ, Schwarz RE. Outcome of palliative operations for malignant bowel obstruction in patients with peritoneal carcinomatosis for nongynecological cancer. Ann Surg Oncol. 2001;8:632
  52. Ringenberg QS, Doll DC, Loy TS, Yarbro JW. Malignant ascites of unknown origin. Cancer. 1989;64:753
  53. Gough IR, Balderson GA. Malignant ascites: a comparison of peritoneovenous shunting and nonoperative management. Cancer. 1993;71:2377
  54. Schumacher DL, Saclarides TJ, Staren ED. Peritoneovenous shunts for palliation in patients with malignant ascites. Ann Surg Oncol. 1994;1:378

PII: S0093-7754(07)00276-X

doi: 10.1053/j.seminoncol.2007.12.007

Seminars in Oncology
Volume 35, Issue 2 , Pages 183-191 , April 2008

Article Tools

* Image Usage & Resolution